|
Exogenous Toxicants and Genetic Susceptibility in ALS Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Exogenous Toxicants and Genetic Susceptibility in ALS conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Exogenous Toxicants and Genetic Susceptibility in ALS Clinical research trials and Exogenous Toxicants and Genetic Susceptibility in ALS healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Exogenous Toxicants and Genetic Susceptibility in ALS. Exogenous Toxicants and Genetic Susceptibility in ALS Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Exogenous Toxicants and Genetic Susceptibility in ALS clinical trial. Test subjects typically receive the most effective healthcare possible for their Exogenous Toxicants and Genetic Susceptibility in ALS condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Exogenous Toxicants and Genetic Susceptibility in ALS  Exogenous Toxicants and Genetic Susceptibility in ALS
Exogenous Toxicants and Genetic Susceptibility in ALS
For Condition: Amyotrophic Lateral Sclerosis
Status: No longer recruiting
Sponsor(s): National Institute of Environmental Health Sciences (NIEHS) ,
Synopsis: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members. The principal objective of this epidemiologic study is to identify environmental and genetic risk factors for ALS. Of primary interest is whether environmental chemicals such as heavy metals, pesticides and organic solvents contribute to the cause of ALS. We also aim to identify genetic factors that contribute to the risk of ALS because individuals with certain genetic traits may be unable to protect against the toxic effects of chemical exposure. Other factors that may protect against the development of ALS, such as dietary antioxidants, are also under investigation. If modifiable factors affecting the risk for ALS could be identified, interventions to delay or even prevent the development of ALS could be developed.
Details: The principal objective of this study is to identify environmental and/or genetic risk factors for amyotrophic lateral sclerosis (ALS). We are addressing this objective by conducting a case-control study of ALS in the Northern California Kaiser Permanente Medical Care Program (KPMCP). Over a four-year period, approximately 175 persons newly diagnosed with ALS will be identified and recruited through physician referrals and computerized mechanisms available within the Kaiser system. The patients with ALS will be compared to a sample of 350 age- and gender-matched persons without ALS from the same membership. Specific study aims are as follows: (1) to investigate the association of ALS with exposure to neurotoxicants including lead, other heavy metals, solvents and pesticides; (2) to determine whether inadequate oxidative defenses for protecting against free-radicals enhance the toxicity of exogenous exposures; (3) to examine the evidence for familial aggregation of neurodegenerative diseases among first-degree relatives of patients with ALS; and (4) to estimate the incidence of ALS in diverse racial and ethnic groups.
Eligibility:
Study Type: Observational, Natural History, Cross-Sectional, Defined Population, Retrospective Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Individuals with ALS within the Kaiser Permanente population of Northern California, ages 18 years and older, with first diagnosis of ALS in the years 1996-2000. Controls are individuals who are age- and sex-matched to the patients with ALS, also from the Kaiser Permanente population.
Total Enrollment: 525
Location and Contact Information:
Additional Information:
Study ID Numbers: 8150-CP-001;
Study Start Date: September 1996
Record last reviewed: February 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00011154
Other Amyotrophic Lateral Sclerosis Studies:
1. IGF-1/ALS Trial
2. Minocycline to Treat Amyotrophic Lateral Sclerosis
3. Creatine for the Treatment of Amyotrophic Lateral Sclerosis
4. Safety testing of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Laughter & Crying)
5. Exogenous Toxicants and Genetic Susceptibility in ALS
Related Studies:
Other Amyotrophic Lateral Sclerosis Clinical Trials
Other Clinical Trials
Other Clinical Trials
Exogenous Toxicants and Genetic Susceptibility in ALS
|
|
|
|
|
|
|
|
